Immuron (IMRN) Income from Non-Controlling Interests (2016 - 2017)
Immuron (IMRN) posted Income from Non-Controlling Interests of $21749.2 for Q4 2017, up 169.63% on a QoQ basis from -$31233.5 in Q4 2016, and up 169.63% year-over-year from $8066.2 in Q4 2016.
Powered by 
Analysis
Immuron (IMRN) Income from Non-Controlling Interests (2016 - 2017) Analysis & Trends
Immuron has reported Income from Non-Controlling Interests for 2 years, with the latest figure at $21749.2 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -100.77 Mn |
| 10 | Immuron | 10.28 Mn | 1.26 Mn | - | - |